[Clinical studies of ceftibuten in the field of urology]

We studied clinical effects and safety of ceftibuten (7432-S, CETB), a new oral cephem antibiotic, against chronic complicated urinary tract infections in 9 cases and bacterial prostatitis in 10 cases. CETB was administered at a daily dose of 400-600 mg divided into twice or 3 times for a duration of 1-4 weeks. The overall clinical effect was 83.3% according to the criteria of UTI Committees (excellent: 4 cases, moderate: 1, poor: 1) in evaluated 6 cases, and the efficacy rate was 77.8% in the bacterial prostatitis cases according to physicians' evaluation (good: 7 cases, fair: 2, unknown: 1). There was 1 case of nausea, vomiting and lightly diarrhea on the third day after treatment but those tendencies all disappeared after stopping administration. So, we concluded that CETB was a useful agent for chronic complicated UTI and bacterial prostatitis with a daily dose level of 400-600 mg except in severe cases.